Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PE L AG O BI OS CI ENCE NEWS / SPRING 2017 Pelago celebrated its 4th Birthday on February 28th 2017 It has been an exciting and successful first 4 years 2013 Company formed, publication of the CETSA method in Science (Martinez Molina et al). First customer and first repeat customer. UK patent granted. 2014 First sub-licenses issued. First 10 customer projects completed. First publication of CETSA HT and CETSA MS methods. US patent granted. 2015 2016 Established the first strategic collaboration with global pharmaceutical company AstraZeneca to benchmark the utility in preclinical drug discovery and screening. European and other patents granted. More than 20 individual customer accounts. Moved to new purpose built offices & state of the art CETSA laboratories. First publications by customers (Pfizer & AstraZeneca) Read more. Completed 100 projects with more than 30 different companies. 2017 Pelago continues to expand, with expected completion of over 200 projects with 50 companies. New collaborations In January we announced that Pelago Bioscience and Sygnature Discovery will collaborate to provide CETSA® based Target Engagement assays to their customers. Sygnature is the UK’s largest independent provider of integrated drug discovery resource and expertise. The collaboration will effectively facilitate the integration of CETSA assays for hit confirmation, lead profiling and biomarker discovery in Sygnature projects. Read full details. Building on Success In a new collaboration with the Karolinska Institute we will build on the expertise used to develop the CETSA HT format and expand its application to develop high throughput automated assays for key signaling proteins important in cell proliferation and metabolism. Read more. CETSA HT delivers the same data as its predecessor, CETSA Classics; but its plate based format, fluorescence readout and significantly lower price point make it a practical solution for screening large numbers of compounds. Pelago offers a CETSA HT assay development services. Once established, the assay can either be run by Pelago or transferred to the customer. The CETSA MS project volume continues to increase as the market appreciates the unique opportunity to selectivity profile compounds against whole proteomes, rapidly elucidating mode of action. We are pushing the boundaries for the analysis format of the 6000 protein profiling campaigns to filter data quantitatively and rank molecular hits on significance. Conferences and meetings AACR Annual meeting 2017, Washington DC 1-5 APRIL 2017 ELRIG Advances in Cell based Screening, Gothenburg 10-11 MAY 2017 Global Discovery To Development Innovation Forum, London 24-25 MAY 2017 Anglo-Nordic Medicinal Chemistry Symposium, Copenhagen 11-14 JUNE 2017 Oxford Global Drug Discovery Summit, Berlin CETSA user meeting 2017, Stockholm 25-26 SEPTEMBER 2017 ELRIG Drug Discovery 2017, Liverpool 3-4 OCTOBER 2017 12-13 JUNE 2017 NLSDays 2017, Malmö 12-14 SEPTEMBER 2017 To me the combination of CETSA with mass spectrometry is the most exciting thing that has happened in drug discovery and proteomics in a long time. Mikhail Savitski, Head of the Proteomics Core Facility at EMBL Heidelberg PELAGO BIOSCIENCE NEWS SPRING 2017